
|Videos|November 17, 2021
Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency
Author(s)Saro Arakelians, PharmD
Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Advertisement
Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5


















































































































